Unicycive Therapeutics, Inc. Common Stock
UNCYUnicycive Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for liver and kidney diseases. The company's portfolio includes innovative therapies aimed at addressing unmet medical needs in chronic liver and renal conditions. Unicycive aims to leverage its expertise in drug development to improve patient outcomes.
Company News
Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations related to false or misleading statements about FDA review of its OLC New Drug Application. The company received a second Complete Response Letter on June 30, 2026, citing manufacturing deficiencies, which led to a stock price decline. Investors who ha...
Block & Leviton is investigating Alignment Healthcare, Inc. (ALHC) for potential securities law violations following allegations that a former executive filed a whistleblower lawsuit claiming the company manipulated finances to boost stock price and executive compensation. The stock fell approximately 16.72% following the report. The firm is also...
Johnson Fistel is investigating Unicycive Therapeutics after the FDA issued a second Complete Response Letter on June 30, 2026, citing the same third-party manufacturing deficiencies from a prior CRL. The FDA had not yet inspected the manufacturing vendor at the time of the resubmission. The announcement led to a decline in Unicycive's stock pric...
Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Soleno Therapeutics for misrepresenting safety profile of drug candidate DCCR/VYKAT XR;...
Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for several publicly traded companies, alleging misleading statements and incomplete disclosures that potentially harmed shareholders.
